D68.020
Von Willebrand disease, type 2A
Clinical Classification Guidelines
Inclusion Terms
- Qualitative defects of von Willebrand factor with decreased platelet adhesion and selective deficiency of high-molecular-weight multimers
Medical Intelligence & Overview
Von Willebrand disease (VWD) is a common inherited bleeding disorder caused by a deficiency or dysfunction of von Willebrand factor (VWF), a protein vital for blood clotting. Type 2A of this condition is characterized by defective VWF that results in impaired platelet adhesion and a selective deficiency of high-molecular-weight multimers, which are crucial for proper clot formation. This form of VWD often leads to increased bleeding tendencies, especially in mucous membranes and skin. Understanding VWD type 2A helps in recognizing symptoms and exploring suitable management strategies.
Causes & Symptoms
Clinical Causes: Inherited genetic mutations affecting the VWF gene Autosomal dominant transmission pattern Alterations leading to qualitative defects in von Willebrand factor, especially affecting high-molecular-weight multimers Potential influence of certain genetic variants that impair the production or stability of VWF multimers
Key Symptoms: Frequent nosebleeds (epistaxis) Easy bruising Bleeding gums Excessive bleeding from cuts or injuries Heavy or prolonged menstrual bleeding Bleeding episodes after surgery or dental procedures Rare joint bleeding compared to other types of VWD
Diagnostic & Treatment
Diagnosis Path: Diagnosis of von Willebrand disease type 2A involves a combination of clinical history and specific laboratory tests including: - **VWF antigen test**: Measures the amount of von Willebrand factor present - **Ristocetin cofactor assay**: Assesses VWF activity - **Multimer analysis**: Evaluates the presence of high-molecular-weight multimers - **Factor VIII activity test**: Since VWF stabilizes factor VIII, decreased levels might be observed - These tests help differentiate type 2A from other variants of VWD and confirm the qualitative defect of VWF. - A thorough family history and genetic testing may also be part of the diagnostic process.
Treatment Protocols: Management of VWD type 2A aims to reduce bleeding risks and manage symptoms, often involving: - **Desmopressin (DDAVP)**: A medication that stimulates the release of VWF stored in blood vessels, suitable for some patients - **VWF concentrates**: Plasma-derived products containing VWF and factor VIII, used in cases where desmopressin is ineffective or contraindicated - **Antifibrinolytic medicines**: Such as tranexamic acid, to prevent clot breakdown during bleeding episodes - **Regular monitoring**: To assess VWF levels and adjust treatment plans accordingly - Patients are advised to inform healthcare providers about their condition before surgeries or dental procedures to ensure appropriate precautions. - It's essential to individualize treatment based on severity, bleeding history, and response to initial therapies.
Clinical Advice & FAQs
Billing Guidance
Is D68.020 a billable ICD-10 code?
Yes, D68.020 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report D68.020?
Clinical documentation must specify the nature of Von Willebrand disease, type 2A and any associated comorbidities for accurate reporting.
Cite this Clinical Reference